



## Original Article



## Role of Corticosteroid in Treatment of Bronchiolitis Presented to Qazi Hussain Ahmad Medical Complex

Abdul Razzaq<sup>1</sup>, Irfan Khan<sup>1</sup>, Maarij Ullah Shah<sup>2\*</sup>, Samia Nawaz<sup>3</sup>, Gul Makay Zaman<sup>4</sup> and Asma Shaukat<sup>5</sup><sup>1</sup>Department of Pediatrics Medicine, Nowshera Medical College, Qazi Hussain Ahmad Medical Complex, Nowshera, Pakistan<sup>2</sup>Department of Pediatrics Medicine, Hayatabad Medical Complex, Khyber Girls Medical College, Peshawar, Pakistan<sup>3</sup>Department of Pharmacology, Gomal Medical College, Dera Ismail Khan, Pakistan<sup>4</sup>Northwest School of Medicine, Peshawar, Pakistan<sup>5</sup>Department of Pharmacology, Women Medical College, Abbottabad, Pakistan

## ARTICLE INFO

**Keywords:**

Acute Bronchiolitis, Corticosteroids, Oral Prednisolone, Infants, Treatment Efficacy, Respiratory Score

**How to Cite:**Razzaq, A., Khan, I., Shah, M. U., Nawaz, S., Zaman, G. M., & Shaukat, A. (2025). Role Of Corticosteroid in Treatment of Bronchiolitis Presented to Qazi Hussain Ahmad Medical Complex: Role Of Corticosteroid in Treatment of Bronchiolitis. *Pakistan Journal of Health Sciences*, 6(7), 144-149. <https://doi.org/10.54393/pjhs.v6i7.3304>**\*Corresponding Author:**Maarij Ullah Shah  
Department of Pediatrics Medicine, Hayatabad Medical Complex, Khyber Girls Medical College, Peshawar, Pakistan  
[maarijshah@gmail.com](mailto:maarijshah@gmail.com)Received Date: 29<sup>th</sup> May, 2025Revision Date: 20<sup>th</sup> July, 2025Acceptance Date: 24<sup>th</sup> July, 2025Published Date: 31<sup>st</sup> July, 2025

## ABSTRACT

Acute bronchiolitis is a major cause of hospitalization in infants and young children, most commonly caused by respiratory syncytial virus (RSV). Despite high spontaneous recovery rates, corticosteroids are frequently used, though their efficacy remains uncertain. **Objective:** To assess the short-term clinical efficacy of oral corticosteroids compared to placebo in infants with acute bronchiolitis. **Methods:** This quasi-experimental study was conducted at the Department of Pediatrics, Qazi Hussain Ahmad Medical Complex, Nowshera. A total of 234 children aged 3 months to 2 years with clinically diagnosed bronchiolitis were enrolled. Participants were allocated to receive either oral prednisolone (1 mg/kg/dose) or placebo twice daily for three days, alongside standard supportive care, including inhaled salbutamol. A blinded examiner assessed treatment response on day 3 using a validated respiratory distress score. Clinical improvement was defined as a reduction of more than two points in the score. **Results:** Clinical improvement was observed in 97.4% of the corticosteroid group and 94.9% of the placebo group. The difference was not statistically significant ( $p=0.308$ ). Subgroup analyses based on gender, maternal education, socioeconomic status, and maternal occupation showed no significant impact on treatment outcomes. **Conclusions:** Oral corticosteroids did not significantly improve clinical outcomes compared to placebo in infants with mild to moderate bronchiolitis. Given the high rate of natural recovery and the potential for adverse effects, routine corticosteroid use is not recommended. Further research is needed to identify specific subgroups that may benefit from targeted steroid therapy.

## INTRODUCTION

Acute bronchiolitis is a leading cause of lower respiratory tract infections in infants and young children, primarily resulting from inflammation and obstruction of the bronchioles. It most commonly affects children under two years of age and remains a major cause of pediatric hospitalization worldwide [1]. The disease typically presents with cough, wheezing, tachypnea (rapid breathing), and chest retractions (inward movement of chest muscles during breathing), which may progress to

respiratory distress in severe cases. While many children recover spontaneously with supportive care, a subset may require hospitalization and even intensive care support in resource-limited settings [2, 3]. Respiratory syncytial virus (RSV) is the most frequently implicated pathogen, accounting for approximately 30-70% of bronchiolitis cases [4]. Other causative agents include parainfluenza viruses, influenza A and B, adenovirus, rhinovirus, coronavirus, and human metapneumovirus. These



infections typically peak in colder seasons, placing a significant burden on healthcare systems, especially during winter months [5]. Inflammation in bronchiolitis is predominantly neutrophilic and can lead to epithelial damage and airway hyper-responsiveness, predisposing some infants to chronic wheezing and asthma later in life [6, 7]. The mainstay of bronchiolitis management remains supportive care, including hydration, oxygen therapy, and monitoring. However, interventions such as bronchodilators and corticosteroids have been frequently used in practice due to their effectiveness in conditions like asthma and croup [1]. Corticosteroids, in particular, are known for their anti-inflammatory effects, including the ability to reduce mucosal edema and limit immune-mediated tissue injury [8]. Despite widespread use, the clinical efficacy of corticosteroids in bronchiolitis remains controversial. While some randomized trials and observational studies have reported modest improvements in respiratory symptoms and hospital stay duration, many others have failed to demonstrate any significant difference when compared with placebo. This inconsistency in outcomes may reflect the heterogeneity of bronchiolitis in terms of viral etiology, host immune response, and disease severity. Consequently, international guidelines, including those from the American Academy of Pediatrics, advise against routine corticosteroid use in typical bronchiolitis cases [9]. In the South Asian region, and particularly within Pakistan, the existing evidence base on this subject remains limited [10]. Although corticosteroids continue to be prescribed for bronchiolitis in many local hospitals, robust local data evaluating their impact are scarce. A study from Pakistan by Ameen, Salahuddin, and Irfan (2025) found no clinical benefit from steroid use in bronchiolitis, highlighting the need for context-specific studies in neighboring populations [11]. To the best of our knowledge, no quasi-experimental study in Pakistan has directly compared oral corticosteroids with placebo in infants diagnosed with bronchiolitis, making this investigation both novel and necessary.

Acute bronchiolitis is a common cause of hospitalization in infants, yet oral corticosteroids continue to be widely prescribed despite inconsistent evidence regarding their effectiveness. In Pakistan, there is limited local research directly comparing corticosteroid therapy with placebo in bronchiolitis management, creating uncertainty in evidence-based pediatric practice. This study aimed to evaluate the short-term clinical efficacy of oral corticosteroids (prednisolone) in infants with mild to moderate bronchiolitis, using a standardized respiratory distress score to assess treatment response. Also, to examine whether demographic or socioeconomic factors

influenced treatment outcomes. In addition, to generate local data that could inform pediatric treatment practices in Pakistan, especially in resource-constrained settings, where corticosteroids are often used without definitive guidance.

## METHODS

This quasi-experimental study was conducted in the Department of Pediatrics at Qazi Hussain Ahmad Medical Complex (QHAMC), Nowshera, from October 2024 to March 2025. The study aimed to evaluate and compare the clinical efficacy of oral corticosteroids versus placebo in children diagnosed with acute bronchiolitis. The study was approved by the Institutional Ethical Review Board (IERB) of QHAMC (Ref. No. 473/IERB/NMC) and by the Research Evaluation Unit (REU) of the College of Physicians and Surgeons Pakistan (Ref. No. CPSP/REU/PED-2022-305-6857). Informed, written consent was obtained from parents or legal guardians of all participants before enrolment. The study was conducted in full accordance with the ethical principles outlined in the Declaration of Helsinki (2013 revision), ensuring the rights, safety, and well-being of the Pediatric participants. Using non-probability consecutive sampling, 234 children aged 3 months to 2 years with clinical features of acute bronchiolitis were enrolled. Patients were non-randomly assigned to two groups based on a predefined allocation protocol maintained by the attending clinical team. The steroid group received oral prednisolone (1 mg/kg/dose) twice daily for 3 days. Placebo group: received a matched placebo solution with the same schedule. Both groups also received standard supportive care, including nebulized salbutamol, hydration, and oxygen therapy if required. Clinical efficacy was defined as a reduction of more than two points in the standardized Respiratory Distress Score after three days of treatment. This composite score (0-9) assessed three parameters: respiratory rate, wheezing, and use of accessory muscles. A reduction of  $\leq 2$  points was classified as no improvement. Inclusion Criteria were age 3 months to 2 years. Clinical diagnosis of bronchiolitis (cough, tachypnea, wheezing or crackles, chest retractions). Respiratory rate  $>60$ /min (for  $<12$  months) or  $>50$ /min (for  $>12$  months) and  $SpO_2 <90\%$  on room air. Exclusion Criteria were suspected or confirmed asthma. Bacterial pneumonia. Illness duration  $>7$  days. Requirement for ICU or ventilatory support. Prematurity or chronic cardiopulmonary/neurological disorders and corticosteroid contraindications. At baseline, demographic details and clinical parameters were recorded. A single, trained pediatrician blinded to treatment allocation assessed respiratory scores on Day 1 and Day 3 to reduce inter-observer variability and bias. Sample size was estimated using an online calculator (UBC

Statistics). Based on prior data showing clinical improvement of 99% in the steroid and 91% in the placebo groups [12], at a 95% confidence level, 80% power, and 5% margin of error, the required sample was 234 (117 in each group). The following formula was used:  $n = [(Z\alpha/2 + Z\beta)^2 \times (p_1(1-p_1) + p_2(1-p_2))] / (p_1 - p_2)^2$ . Where:  $n$  = required sample size per group,  $Z\alpha/2$  = Z-value for desired confidence level (e.g., 1.96 for 95%),  $Z\beta$  = Z-value for desired power (e.g., 0.84 for 80%),  $p_1$  = expected proportion in group 1 (e.g., steroid group),  $p_2$  = expected proportion in group 2 (e.g., placebo group) and  $(p_1 - p_2)$  = effect size (difference between two proportions).  $p_1 = 0.99$  and  $p_2 = 0.91$ ,  $Z\alpha/2 = 1.96$ ,  $Z\beta = 0.84$ .  $n = [(1.96 + 0.84)^2 \times (0.99 \times 0.01 + 0.91 \times 0.09)] / (0.99 - 0.91)^2$   $n$  = required sample size per group = 117. Total sample = 234 participants. All data were analyzed using SPSS version 25.0. The Shapiro-Wilk test was used to assess normality for quantitative variables (age, weight, hospital stay). As the data were not normally distributed, results were reported as medians (IQRs) and analyzed using non-parametric tests. Descriptive statistics were applied to demographic data. Clinical efficacy (primary outcome) was compared between groups using the Chi-square test, and Fisher's Exact Test was used when expected counts were <5. Cramer's V was calculated for the effect size. A p-value <0.050 was considered statistically significant.

## RESULTS

A total of 234 children aged 3 months to 2 years with clinically diagnosed bronchiolitis were included in this quasi-experimental study. Participants were equally assigned to either the corticosteroid group (n=117) or the placebo group (n=117). The overall cohort included slightly more female (53%) than male (47%). Most mothers had either an elementary (27.8%) or a graduate (25.6%) education. Regarding economic status, 36.3% were classified as well-off, 35.9% as middle-income, and 27.8% as poor. The majority of participants lived in rural areas (53.8%). In terms of maternal occupation, 35.5% were housewives, 34.6% manual workers, and 29.9% were employed in executive roles (Table 1).

**Table 1:** Descriptive Statistics of Categorical Variables (n=234)

Variables	Category	n (%)
Study Group	Corticosteroid	117 (50.0%)
	Placebo	117 (50.0%)
Gender	Female	124 (53.0%)
	Male	110 (47.0%)
Mother's Education	Elementary	65 (27.8%)
	Graduate	60 (25.6%)
	Highly Educated	55 (23.5%)
	Uneducated	54 (23.1%)
Economic Status	Well-off	85 (36.3%)

	Middle-income	84 (35.9%)
	Poor	65 (27.8%)
Living Area	Rural	126 (53.8%)
	Urban	108 (46.2%)
Maternal Profession	Housewife	83 (35.5%)
	Manual Worker	81 (34.6%)
	Executive	70 (29.9%)
Treatment Outcome	Improved	225 (96.2%)
	Not Improved	9 (3.8%)

The median age of participants was 12 months (IQR=11), and mean age was  $12.43 \pm 6.22$  months. Median weight was 9.8 kg (IQR=4.9) and mean weight was  $9.94 \pm 2.88$  kg. Median duration of hospital stay was 2 days (IQR=0.0), with a mean of  $2.09 \pm 0.46$  days. All variables were non-normally distributed based on the Shapiro-Wilk test (Table 2).

**Table 2:** Descriptive Statistics of Quantitative Variables (n=234)

Variable	Median (IQR)	Mean $\pm$ SD
Age (Months)	12 (11)	$12.43 \pm 6.22$
Weight (kg)	9.8 (4.9)	$9.94 \pm 2.88$
Hospital Stay (Days)	2.0 (0.0)	$2.09 \pm 0.46$

Clinical improvement was defined as a >2-point reduction in the standardized respiratory distress score by Day 3. A total of 225 children (96.2%) met this criterion. The corticosteroid group showed an improvement rate of 97.4%, compared to 94.9% in the placebo group. However, this difference was not statistically significant ( $\chi^2 = 1.04$ ,  $p=0.308$ ). Fisher's Exact Test confirmed the non-significance due to small cell counts, and the effect size (Cramer's V=0.067) indicated a very weak association between treatment and outcome. Subgroup comparisons were conducted across gender, maternal education, economic status, residence, and maternal occupation. While some numeric differences were noted, none were statistically significant (Table 3).

**Table 3:** Subgroup Comparison of Treatment Efficacy (n=234)

Subgroups	Category	Improved n (%)	Not Improved n (%)	Chi-square (p-value)
Overall	Corticosteroid	114 (97.4%)	3 (2.6%)	1.04 (p=0.308)
	Placebo	111 (94.9%)	6 (5.1%)	
Female	Corticosteroid	58 (96.7%)	2 (3.3%)	0.004 (p=0.948)
	Placebo	62 (96.9%)	2 (3.1%)	
Male	Corticosteroid	56 (98.2%)	1 (1.8%)	2.124 (p=0.145)
	Placebo	49 (92.5%)	4 (7.5%)	
Mother's Education: Elementary	Corticosteroid	32 (100.0%)	0 (0.0%)	3.050 (p=0.081)
	Placebo	30 (90.9%)	3 (9.1%)	
Graduate	Corticosteroid	32 (97.0%)	1 (3.0%)	0.021 (p=0.885)
	Placebo	26 (96.3%)	1 (3.7%)	
Highly Educated	Corticosteroid	23 (92.0%)	2 (8.0%)	0.576 (p=0.448)
	Placebo	29 (96.7%)	1 (3.3%)	

Uneducated	Corticosteroid	27(100.0%)	0(0.0%)	1,019 (p=0.313)
	Placebo	26(96.3%)	1(3.7%)	
Economic Status: Poor	Corticosteroid	43(97.7%)	1(2.3%)	0,485 (p=0.486)
	Placebo	21(100.0%)	0(0.0%)	
Middle-income	Corticosteroid	28(100.0%)	0(0.0%)	1,024 (p=0.311)
	Placebo	54(96.4%)	2(3.6%)	
Well-off	Corticosteroid	43(95.6%)	2(4.4%)	0,996 (p=0.318)
	Placebo	36(90.0%)	4(10.0%)	
Living Area: Rural	Corticosteroid	66(98.5%)	1(1.5%)	1,317 (p=0.251)
	Placebo	56(94.9%)	3(5.1%)	
Urban	Corticosteroid	48(96.0%)	2(4.0%)	0,084 (p=0.772)
	Placebo	55(94.8%)	3(5.2%)	
Maternal Profession: Executive	Corticosteroid	43(97.7%)	1(2.3%)	1,170 (p=0.279)
	Placebo	24(92.3%)	2(7.7%)	
Housewife	Corticosteroid	34(97.1%)	1(2.9%)	0,508 (p=0.476)
	Placebo	45(93.8%)	3(6.3%)	
Manual Worker	Corticosteroid	37(97.4%)	1(2.6%)	0,008 (p=0.929)
	Placebo	42(97.7%)	1(2.3%)	

The finding illustrates the proportion of children who improved in both groups. While both arms demonstrated high efficacy, the steroid group had fewer non-responders (2.6%) than the placebo group (5.1%). Though not statistically significant, this trend suggests a possible clinical benefit in some subgroups. The majority in both groups improved, with a slightly higher number of non-improved cases in the Placebo group (Figure 1).

Treatment Efficacy by Intervention Group




Figure 1: Improvement Versus No Improvement Across the Steroid and Placebo Groups

## DISCUSSION

This quasi-experimental study evaluated the short-term clinical efficacy of oral corticosteroids in infants with acute bronchiolitis. Among the 234 enrolled participants, both treatment groups showed high rates of clinical improvement by Day 3, with no statistically significant difference between the corticosteroid (97.4%) and placebo (94.9%) groups (p=0.308). Subgroup analyses across gender, maternal education, economic status, residential status, and maternal profession similarly showed no significant variation in outcomes. These findings were

consistent with international clinical guidelines, such as those of the American Academy of Pediatrics, which recommend against the routine use of corticosteroids in bronchiolitis due to lack of proven benefit in most cases [12]. Multicenter trials and meta-analyses support this recommendation, highlighting the self-limiting nature of bronchiolitis and the high rate of spontaneous clinical resolution without pharmacological intervention [13-15]. Regionally, there was a noticeable scarcity of robust clinical studies on this topic in the Pakistani setting. However, limited data from tertiary care centers in South Asia mirror our results. For instance, Hasan et al. from Bangladesh observed widespread steroid use in pediatric bronchiolitis with no significant clinical advantage [16]. To our knowledge, this was among the first quasi-experimental studies in Pakistan specifically comparing oral corticosteroids and placebo for bronchiolitis in a controlled setting, thereby contributing much-needed local evidence. Internationally, some studies have suggested that corticosteroids may have a selective benefit in particular patient subgroups. Gelbart et al. found that in children with severe bronchiolitis requiring ventilation, corticosteroids may reduce the duration of respiratory support [17]. Others suggest a possible benefit in children with rhinovirus-associated bronchiolitis or first-time wheezers older than six months [18, 19]. However, these findings are not universally applicable and require more precise patient stratification. Our study reinforces the understanding that bronchiolitis is a clinically heterogeneous illness. Unlike asthma or croup, which respond predictably to anti-inflammatory therapy, bronchiolitis may involve variable viral triggers, age-related immune responses, and differing inflammatory profiles [20, 21]. Therefore, a uniform corticosteroid approach may not be justified for the general pediatric population. Importantly, the safety profile of corticosteroids must be carefully considered. Even short-term use may increase the risk of hyperglycemia, secondary infection, or other adverse effects [22]. Although our study did not record significant adverse events, the absence of added benefit makes such risks less acceptable in routine practice. Strengths of this study include a relatively large sample size, clear inclusion/exclusion criteria, blinded outcome assessment, and the use of a standardized clinical scoring system. This enhances the reliability and reproducibility of findings. The study was limited by its quasi-experimental design, non-randomized participant allocation, short follow-up duration, and focus on mild to moderate cases from a single medical center, which may reduce generalizability. Additionally, long-term respiratory outcomes and potential adverse effects of corticosteroids were not fully explored. Future research should involve multicenter randomized

controlled trials with larger diverse populations, longer follow-up periods, and subgroup analyses to identify specific patient groups that may benefit from corticosteroid therapy. This would strengthen treatment guidelines and optimize bronchiolitis management practices.

## CONCLUSIONS

Oral corticosteroids showed no statistically significant benefit over placebo in infants with mild to moderate bronchiolitis over a short-term period. While both treatment groups demonstrated high rates of clinical improvement, the findings suggest that routine corticosteroid use offers limited additional advantage and should be approached cautiously. Given the self-limiting nature of bronchiolitis and the potential for adverse effects, corticosteroids should not be routinely prescribed in such cases.

## Authors' Contribution

Conceptualization: AR

Methodology: MUS, GMZ, AS

Formal analysis: AR, IK, SN

Writing and Drafting: AR, IK, GMZ, AS

Review and Editing: AR, IK, GMZ, AS

All authors approved the final manuscript and take responsibility for the integrity of the work

## Conflicts of Interest

All the authors declare no conflict of interest.

## Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

## REFERENCES

- [1] Imran M, Qaisrani MS, Nayyar ZA, Najam M, Pasha W, Imran S. Evaluating the Efficacy of Corticosteroids and Bronchodilators in the Management of Paediatric Bronchiolitis: A Randomized Controlled Trial. *International Journal of Health Sciences*.2023;7(S1): 2140-50. doi: 10.53730/ijhs.v7nS1.14465.
- [2] Amir M, Akhater N, Sodhar JM, Shuja A, Maqsood M. Interventions in Early Diagnosis and Treatment of Acute Respiratory Tract Infections in Children Under 5 Years of Age. *Pakistan Journal of Medical and Health Sciences*.2022 Mar;16(02):566-.doi:10.5335 0/pjmhs22162566.
- [3] Dall'olio C, Sant'anna M, Sant'anna C. Treatment of Acute Viral Bronchiolitis. *Residência Pediátrica*. 2021;11(3).doi:10.25060/residpediatr-2021.v11n3-186.
- [4] Zheng H, Yu X, Chen Y, Lin W, Liu L. Effects of Inhaled Corticosteroids on Lung Function in Children with Post-Infectious Bronchiolitis Obliterans in Remission.*Frontiers in Pediatrics*.2022May;10:827 508. doi: 10.3389/fped.2022.827508.
- [5] Hassan MA, Younis MM, Ahmed DH. Role of Oral Prednisolone in Treatment of Acute Bronchiolitis in Children with and without Family History of Atopy. *Al-Azhar Journal of Pediatrics*.2021Apr;24(2):2019-2036.
- [6] Plint AC, Heath A, Rowe T, Vogel KI, Wills-Ibarra N, O'Brien S et al. A Randomised Controlled Trial Comparing Epinephrine and Dexamethasone to Placebo in the Treatment of Infants with Bronchiolitis: the Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone (BIPED) Study Protocol. *European Respiratory Society Open Research*.2025Mar.doi:10.1101/2024.12.05.24318262.
- [7] G'ofurjonov M. Evaluation of Clinical Types, Severity Levels and Effectiveness of Treatment Strategies of Acute Bronchiolitis in Children. *Modern Science and Research*. 2025 May; 4(5): 80-4.
- [8] Choudhary S, Liaqat I, Muntaha ST, Ahmad R, Niazi J, Mansoor M. Randomised Trial: Adrenaline and Dexamethasone Vs. Adrenaline in Children with Bronchiolitis. *Journal of Rawalpindi Medical College*. 2024 Dec; 28(4). doi: 10.37939/jrhc.v28i4.2512.
- [9] Angurana SK, Williams V, Takia L. Acute Viral Bronchiolitis: A Narrative Review. *Journal of Pediatric Intensive Care*. 2023 Jun; 12(02): 079-86. doi: 10.1055/s-0040-1715852.
- [10] Qureshi AN, Khan HI, Mahboob A. Comparison of Mean Duration of Bronchiolitis in Children Receiving Standard Treatment with and without Intravenous Steroids.2023.
- [11] Ameen U, Salahuddin M, Irfan M. Inhaled Therapies for Cough Resolution in Acute Bronchitis: Single Center Cross-Sectional Study from Pakistan. *Khyber Journal of Medical Sciences*.2025 Apr; 18(1): 37-41. doi: 10.70520/kjms.v18i1.605.
- [12] Teeratakulpisarn J, Limwattananon C, Tanupattarachai S, Limwattananon S, Teeratakulpisarn S, Kosalaraksa P. Efficacy of Dexamethasone Injection for Acute Bronchiolitis in Hospitalized Children: A Randomized, Double-Blind, Placebo-Controlled Trial.*Pediatric Pulmonology*.20 07 May; 42(5): 433-9. doi: 10.1002/ppul.20585.
- [13] Guitart C, Alejandre C, Torrús I, Balaguer M, Esteban E, Cambra FJ et al. Impact of a Modification of the Clinical Practice Guide of the American Academy of Pediatrics in the Management of Severe Acute Bronchiolitis in A Pediatric Intensive Care Unit. *Medicina Intensiva (English Edition)*.2021Jun;45(5): 289-97. doi: 10.1016/j.medine.2019.10.008.
- [14] Jiang F, Mao W, Wan Y, Yang Q, Fan F, Huang Z. Effect of Glucocorticoids on Anti-Infective Efficacy and

- Prognosis of Children with Bronchiolitis Caused by Mycoplasma Pneumoniae. *Tropical Journal of Pharmaceutical Research*. 2024 Sep; 23(8): 1331-6. doi: 10.4314/tjpr.v23i8.13.
- [15] Ambrožej D, Makrinioti H, Whitehouse A, Papadopoulos N, Ruszczyński M, Adamiec A, Castro-Rodriguez JA, Alansari K, Jartti T, Feleszko W. Respiratory virus type to guide predictive enrichment approaches in the management of the first episode of bronchiolitis: a systematic review. *Frontiers in Immunology*. 2022 Oct 27; 13: 1017325. doi: 10.3389/fimmu.2022.1017325.
- [16] Hasan KZ, Mollah MA, Hossain MM, Alam MZ, Ahmed MF. Efficacy of Prednisolone in Recovery from Acute Bronchiolitis: Study in A Tertiary Care Hospital, Dhaka, Bangladesh. *American Journal of Pediatrics*. 2021; 7(2): 85. doi: 10.11648/j.ajp.20210702.19.
- [17] Gelbart B, McSharry B, Delzoppo C, Erickson S, Lee K, Butt W et al. Pragmatic Randomized Trial of Corticosteroids and Inhaled Epinephrine for Bronchiolitis in Children in Intensive Care. *The Journal of Pediatrics*. 2022 May; 244: 17-23. doi: 10.1016/j.jpeds.2022.01.031.
- [18] Bottau P, Liotti L, Laderchi E, Palpacelli A, Calamelli E, Colombo C et al. Something Is Changing in Viral Infant Bronchiolitis Approach. *Frontiers in Pediatrics*. 2022 Apr; 10: 865977. doi: 10.3389/fped.2022.865977.
- [19] Lee B, Turner S, Borland M, Csonka P, Grigg J, Guilbert TW et al. Efficacy of Oral Corticosteroids for Acute Preschool Wheeze: A Systematic Review and Individual Participant Data Meta-Analysis of Randomised Clinical Trials. *The Lancet Respiratory Medicine*. 2024 Jun; 12(6): 444-56. doi: 10.1016/S2213-2600(24)00041-9.
- [20] Kocaoğlu Ç. The Use of High-Dose Corticosteroids in Seriously Ill Children with Acute Viral Bronchiolitis. *Journal of Pediatric Emergency and Intensive Care Medicine*. 2020 Jun. doi: 10.4274/cayd.galenos.2019.92485.
- [21] Haskell EL. Improving the Care of Infants with Bronchiolitis (Doctoral Dissertation, The University of Auckland). 2021.
- [22] Dvorin EL and Ebell MH. Short-Term Systemic Corticosteroids: Appropriate Use in Primary Care. *American Family Physician*. 2020 Jan; 101(2): 89-94.